F20.0
Conditions
Interventions
Group 1: After giving written informed consent, 20 early onset and chronically ill schizophrenia patients (SZ) (Arm 1) and 20 matched healthy controls (HC) (Arm 2) aged between 18-45 years will be inc
ICF, intracortical facilitation) will be recorded. Afterwards, either tDCS or PAS stimulation will be applied on the primary motor cortex in a randomised order. Following plasticity inducing stimulati
Sponsors
Forschungsdekanat derLudwig-Maximilians-Universität München
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: General inclusion criteria: - Adults 18-45 yrs. - Ability to understand the study information and to give written informed consent Special inclusion criteria: - Patients meeting the ICD-10 diagnostic criteria of schizophrenia - duration of illness under 2 years in the case of early disease stage - stabel medication for at least one week prior to inclusion in the study in the case of chronically ill patients - in the case of legal supervision by a medical or social care professional written informed consent has to be given by both, the patient and the caregiver/supervisor/lawyer.
Exclusion criteria
Exclusion criteria: - Children ( 45 yrs. - Pregnancy - Participation in an interventional study involving neuroactive medications within the last 6 months. - Neurological disorders: diagnosis of epilepsy, severe brain injury, brain operation or brain implants, Parkinson‘s, increased intracranial pressure, TIA or stroke, subdural haematomas, infarction or haemorrhage, tumour, on-going acute or chronic infection, cerebral palsy or any other neurological deficit. - Psychiatric disorders: Diagnosis of depression, delusional disorder, anxiety disorder, dementia, organic psychiatric illness or drug dependency (with the exclusion of tobacco dependency). - Other severe medical conditions: Diagnosis of cardiovascular disorder, especially hypotonia or hypertension, pace maker, implanted cardioverter-defibrillator (ICD) or other implanted devices, respiratory disorders, especially asthma, chronic obstructive pulmonary disease (COPD), severe on-going , systemic skin disease (neurodermitis, psoriasis) or bone-structure involving diseases (Pagets, osteoporosis). Special exclusion criteria for healthy controls: any known psychiatric illness according to ICD-10 criteria. A screening using the MINI-Plus interview will be conducted.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Completion of study and development of LTP-like plasticity (long-term-potentiation, LTP) follwoing with both interventions (PAS, tDCS) and all TMS-measurements. | — |
Secondary
| Measure | Time frame |
|---|---|
| Impact of disease state on develeopment of neural plasticity. | — |
Countries
Germany
Contacts
Public ContactWolfgang Strube
Psychiatrische KlinikLudwig-Maximilians-Universität München
Outcome results
None listed